Study Overview

The TRIUMPH trial is investigating whether a drug called mycophenolate mofetil can help women aged 18 to 50 with an underactive thyroid who continue to experience symptoms such as tiredness, lethargy, weight issues, aches and pains and 'brain fog'. The study is exploring whether ongoing inflammation in the thyroid might be causing these symptoms and if mycophenolate mofetil can help reduce the inflammation and help patients feel better.

Mycophenolate mofetil is used to treat many inflammatory and immune related conditions like arthritis and autoimmune liver disease. It has not been used in people with Hashimoto’s Thyroiditis before, but it has been safely used for over 25 years.

If you are eligible to take part, you will be randomly allocated to take either mycophenolate mofetil or placebo (a ‘dummy’ treatment) tablets. If you are allocated the placebo, you will not get any direct benefit from the treatment. The TRIUMPH trial is a “double-blinded” study, which means that neither you nor your doctors will know which treatment you are taking until the last participant has completed all visit in the trial.

A total of 48 people will join the trial. Most will get the drug mycophenolate (30 people), and 18 will get a placebo (a dummy pill). You will take a tablet twice a day for four months. Neither you nor your doctors will know which treatment you are getting until the trial is finished.